
Flash Report
-1Q Results and FY15 Outlook-


Teijin Limited
July 31, 2015

Outline of FY15 1Q Results

(1) Consolidated Results Highlights

(¥ billion)

Quarterly Movement



◆ Operating results

(¥ billion)	FY14 1Q	FY15 1Q	Difference
Net sales	181.9	192.6	+10.7
Operating income	4.8	16.4	+11.6
OP margin	2.6%	8.5%	+5.9%
Nonoperating items (net)	(0.2)	1.6	+1.7
Ordinary income	4.7	18.0	+13.3
Extraordinary items (net)	(0.8)	(1.3)	-0.5
Income before income taxes	3.9	16.7	+12.8
Income taxes	2.4	5.5	+3.1
Profit (loss) attributable to non-controlling interests	(0.1)	0.0	+0.2
Profit attributable to owners of parent	1.6	11.2	+9.5
EPS (¥)	1.68	11.39	+9.71

EBITDA *1	15.9	25.9	+10.0
CAPEX *2	6.2	6.7	+0.5
Depreciation & amortization	11.1	9.5	-1.6
R&D expenses	7.7	8.0	+0.3
FCF	(21.5)	5.4	+26.9

- Net sales: Rose, owing to
 - Increases in the Healthcare and Trading and Retail segments, although sales in materials businesses were generally flat
- Operating income, ordinary income and profit attributable to owners of parent: Up sharply, underpinned by
 - Substantial increases in our materials businesses, which reflected falling prices for fuel and raw materials, and the positive impact of restructuring initiatives
 - Steady gains in our healthcare business, thanks to robust results for core products and services

◇ PL exchange rate

	FY14 1Q	FY15 1Q
¥/US\$	102	121
¥/€	140	134
US\$/€	1.37	1.11

*1 EBITDA = Operating income + Depreciation & amortization

*2 CAPEX includes investments in intangible assets

◆ Nonoperating items

(¥ billion)	FY14 1Q	FY15 1Q	Difference
Interest income	0.1	0.2	+0.0
Dividends income	0.7	0.9	+0.2
Equity in earnings of affiliates	0.4	0.9	+0.5
Foreign exchange gains	—	0.2	+0.2
Others	0.2	0.6	+0.4
Nonoperating income, total	1.5	2.8	+1.4
Interest expenses	0.7	0.6	-0.1
Foreign exchange losses	0.0	—	-0.0
Others	0.9	0.6	-0.3
Nonoperating expenses, total	1.6	1.3	-0.4
Nonoperating items, total	(0.2)	1.6	+1.7

◆ Extraordinary items

(¥ billion)	FY14 1Q	FY15 1Q	Difference
Gain on sales of noncurrent assets	0.0	0.1	+0.0
Gain on sales of investment securities	0.0	0.0	-0.0
Reversal of provision for business structure improvement	—	0.1	+0.1
Others	0.0	0.0	+0.0
Extraordinary income, total	0.1	0.2	+0.1
Loss on sales and retirement of noncurrent assets	0.1	0.3	+0.2
Impairment loss	0.2	0.5	+0.3
Business structure improvement expenses	0.6	0.4	-0.2
Others	0.0	0.3	+0.3
Extraordinary losses, total	0.9	1.5	+0.6
Extraordinary items, total	(0.8)	(1.3)	-0.5


◆ Financial position

(¥ billion)	March. 31, 2015	June. 30, 2015	Difference	(Impact of foreign exchange rate)
Total assets	823.7	816.4	-7.3	+6.0
Shareholders' equity	287.1	302.8	+15.7	+2.7
Interest-bearing debt	308.2	294.3	-13.9	+1.7
D/E ratio	1.07	0.97	-0.10	
Shareholders' equity ratio	34.9%	37.1%	+2.2%	

◆ Cash flows

(¥ billion)	FY14 1Q	FY15 1Q	Difference
Operating activities	4.8	12.5	+7.6
Investing activities	(26.4)	(7.1)	+19.3
FCF	(21.5)	5.4	+26.9
Financing activities	21.8	(19.3)	-41.1
Cash & cash equivalents	0.3	(13.9)	-14.2

◇ Analysis of changes in total assets




◇ BS exchange rate

	March. 31, 2015	June. 30, 2015
JPY / USD	120	122
JPY / EUR	130	137
USD / EUR	1.08	1.12

◆ Analysis of changes in operating income

Increased sales, particularly in the Healthcare segment, and falling prices for raw materials and fuel across all of our materials businesses contributed to a significant increase in operating income



(2) Operating Results by Segment (Comparison with FY14 1Q)


Net sales Operating income (loss)	Net sales				Operating income (loss)			
	FY14 1Q	FY15 1Q	Difference	% Change	FY14 1Q	FY15 1Q	Difference	% Change
(¥ billion)								
Advanced Fibers and Composites	31.4	32.1	+0.7	+2.2%	1.7	3.6	+2.0	+117.6%
Electronics Materials and Performance Polymer Products	46.2	44.8	-1.4	-3.1%	0.7	6.2	+5.5	+752.8%
Healthcare	33.2	38.0	+4.7	+14.3%	5.7	8.9	+3.2	+56.9%
Trading and Retail	57.5	61.4	+3.9	+6.8%	0.8	1.0	+0.3	+38.5%
Total	168.4	176.3	+7.9	+4.7%	8.8	19.7	+10.9	+124.4%
Others	13.5	16.3	+2.8	+20.7%	(0.7)	0.5	+1.2	—
Elimination and Corporate	—	—	—	—	(3.3)	(3.9)	-0.6	—
Total	181.9	192.6	+10.7	+5.9%	4.8	16.4	+11.6	+241.0%

① Advanced Fibers and Composites

Net sales

Operating income

(¥ billion)



(¥ billion)	14/1Q	15/1Q	Difference	Change
Net sales	31.4	32.1	+0.7	+2.2%
Operating income	1.7	3.6	+2.0	+117.6%

◆ Summary & Actions

◇ High-Performance Fibers

Para-aramid fibers:

- Sales for automotive applications were up in Europe, as were sales for infrastructure-related applications
- Sales for use in ballistic protection products were stable

Meta-aramid fibers:

- Sales for use in protective clothing and for industrial applications remained solid

Polyester fibers:

- Operating income remained firm, thanks to increased sales for use in personal hygiene products and in membrane support layers for water treatment applications and to the positive impact of cost reductions, although polyester fibers for automotive applications struggled

◇ Carbon Fibers and Composites


- Sales for use in aircraft were favorable, as were sales for use in sports and leisure equipment in Asia
- Steady progress was made in thermoplastic CFRP projects

② Electronics Materials and Performance Polymer Products

Net sales

Operating income

(¥ billion)



(¥ billion)	14/1Q	15/1Q	Difference	Change
Net sales	46.2	44.8	-1.4	-3.1%
Operating income	0.7	6.2	+5.5	+752.8%

◆ Summary & Actions

◇ Resin and Plastics Processing

Polycarbonate resin:

- Operating income rallied sharply, bolstered by falling prices for key raw materials and the positive impact of an improved sales mix and ongoing restructuring initiatives

Processed plastics and specialty polycarbonate resin:

- Sales of indium tin oxide (ITO) films on polycarbonate substrates for use in capacitive touch screens expanded
- Sales of specialty polycarbonate resin for use in smartphone camera lenses were firm

◇ Films

- Reflective films for use in LCD televisions struggled, as pricing competition intensified, while demand for products used in specialty packaging and magnetic materials remained listless
- Sales of release films for manufacturing processes remained firm for use in multilayer ceramic capacitors and polarizers
- Preparations for the integration of domestic production facilities—which include narrowing our focus to high-value-added products—progressed


③ Healthcare

Net sales

Operating income

(¥ billion)

(¥ billion)	14/1Q	15/1Q	Difference	Change
Net sales	33.2	38.0	+4.7	+14.3%
Operating income	5.7	8.9	+3.2	+56.9%



◆ Summary & Actions

◇ Pharmaceuticals

- Sales of newly developed drugs, including hyperuricemia and gout treatment febuxostat and *Somatuline*, a treatment for acromegaly, continued to expand steadily
- Efforts to expand product portfolio by developing new formulations for existing drugs continued
- Existing drugs struggled, hampered by rising sales of generic drugs

◇ Home Healthcare


- HOT: Rental volume remained firm, while efforts focused on marketing a portable HOT device
- CPAP ventilators: Rental volume rose steadily
- Operating conditions in the United States remained harsh; in response, we continued taking steps to restore profitability, including integrating sales bases and reducing headcount

④ Trading and Retail

Net sales

Operating income

(¥ billion)



(¥ billion)	14/1Q	15/1Q	Difference	Change
Net sales	57.5	61.4	+3.9	+6.8%
Operating income	0.8	1.0	+0.3	+38.5%

◆ Summary & Actions

◇ Fiber Materials and Apparel

- With sales of fiber materials brisk to manufacturers of sportswear and outdoor apparel in the Americas and Europe, efforts focused on expanding sales of products for use in 2016 fall and winter apparel
- Textiles continued to struggle, owing to yen depreciation, which pushed up the cost of imports, and to a downturn in the Japanese retail market following the April 2014 consumption tax hike
- Efforts were made to augment supply capabilities in the ASEAN region and to fortify our original design manufacturer (ODM) business by maximizing our materials development capabilities

◇ Industrial Textiles and Materials


- Sales of general-purpose and household materials remained healthy
- Sales for automotive applications were robust early on but slowed toward the end of the quarter
- Collaboration with our healthcare business commenced in the area of comprehensive medical and nursing care services

(3) Strategic measures (from April 2015 forward)

Strategic businesses

■ Carbon fibers: Accelerate product development to capitalize on expanding sales for prepreg

- Market new carbon fiber with superb tensile strength and high modulus of elasticity (responds to the exacting requirements of aircraft and automobile manufacturers)



Prepreg

■ Pharmaceuticals: Reinforce and expand development pipeline

- Launch reduced-size extended-release tablet-form version of expectorant *Mucosolvan* (small, easy-to-swallow tablet requiring only a once-daily dosage to maintain efficacy)
- Expand indications for febuxostat in Europe (obtain approval to market for use in preventing and treating tumor lysis syndrome (TLS)-associated hyperuricemia; marketing protection period extended)
- Commence clinical trials in Japan for TMX-049 (next-generation treatment for hyperuricemia and gout)

*Mucosolvan L* (right)

New businesses

■ Broaden applications for *CELL FORM*, an RFID-enabled two-dimensional communication sheet

- Begin sales of *PaperBeacon*, the world's first sheet-form authentication beacon (users simply lay their smartphones or tablet computers on a *PaperBeacon*-equipped surface to be authenticated for network connection)
- Expand deployment of *CELL FORM* into the healthcare business (develop real-time management systems for medical equipment, among others)

■ Establish full-scale membrane business

- Launch *MIRAIM* microporous membrane (promote use in applications such as filters for removal of foreign matter and sheet-form cell culture media)



Outlook for FY15

◆ Summary of outlook for FY15

Despite an uncertain economic outlook, we have revised our full-term forecasts for fiscal 2015 in light of an expected upturn in the first half attributable to factors such as falling prices for raw materials in our materials businesses.

	FY14	FY15 Outlook	Difference	
			Amount	%
(¥ billion)				
Net sales	786.2	810.0	+23.8	+3.0%
Operating income	39.1	53.0	+13.9	+35.6%
Operating margin	5.0%	6.5%	—	+1.5%
Ordinary income	42.4	53.0	+10.6	+25.1%
Profit (loss) attributable to owners of parent	(8.1)	30.0	+38.1	—
CAPEX *1	28.1	44.0	+15.9	
Depreciation & amortization	43.0	40.0	-3.0	
R&D expenses	32.4	34.0	+1.6	
FCF	26.4	15.0	-11.4	


*1 CAPEX includes investments in intangible assets

FY15 Previous Outlook*2	Difference (Amount)
825.0	-15.0
47.5	+5.5
5.8%	—
47.5	+5.5
25.0	+5.0
44.0	—
40.0	—
34.0	—
10.0	+5.0

*2 Announced on May 8, 2015

- ◇ Outlook for cash dividends: No change (annual dividend of ¥6.00 per share, comprising interim and year-end dividends of ¥3.00 per share each)
- ◇ Underlying assumptions: Exchange rates of ¥120 to US\$1.00, ¥135 to €1.00 and an average Dubai crude oil price of US\$64 per barrel

◆ Movement of results




◆ Changes in net sales and operating income for FY14–FY15

		FY14 Results			FY15 Outlook			Difference
		1H	2H	Total	1H	2H	Total	
		(¥ billion)						
Net sales	Advanced Fibers and Composites	64.4	71.1	135.5	65.0	75.0	140.0	+4.5
	Electronics Materials and Performance Polymer Products	92.2	92.6	184.8	85.0	85.0	170.0	-14.8
	Healthcare	67.8	73.9	141.7	75.0	75.0	150.0	+8.3
	Trading and Retail	123.6	135.8	259.4	130.0	145.0	275.0	+15.6
	Total	348.0	373.4	721.4	355.0	380.0	735.0	+13.6
	Others	29.4	35.4	64.8	35.0	40.0	75.0	+10.2
Total		377.4	408.8	786.2	390.0	420.0	810.0	+23.8
Operating income (loss)	Advanced Fibers and Composites	4.7	9.7	14.4	8.5	10.0	18.5	+4.1
	Electronics Materials and Performance Polymer Products	(1.3)	4.7	3.4	9.5	3.5	13.0	+9.6
	Healthcare	12.1	12.7	24.8	15.5	11.5	27.0	+2.2
	Trading and Retail	2.0	2.3	4.2	1.5	3.5	5.0	+0.8
	Total	17.4	29.4	46.8	35.0	28.5	63.5	+16.7
	Others	0.5	3.5	4.0	1.5	4.0	5.5	+1.5
	Elimination and Corporate	(5.8)	(6.0)	(11.7)	(8.5)	(7.5)	(16.0)	-4.3
Total		12.1	27.0	39.1	28.0	25.0	53.0	+13.9


◆ Analysis of changes in operating income forecast

➤ Comparison with FY14

(¥ billion)



➤ Comparison with previous forecast



◆ Financial highlights

	FY11 Actual	FY12 Actual	FY13 Actual	FY14 Actual	FY15 Outlook
ROA *1	4.5%	1.6%	2.4%	4.9%	6.3%
ROE *2	4.2%	-10.3%	3.0%	-2.8%	10.0%
Operating margin	4.0%	1.7%	2.3%	5.0%	6.5%
D/E ratio	0.89	1.00	1.00	1.07	1.0
Shareholders' equity ratio	38.3%	35.6%	36.7%	34.9%	36.0%
Earnings per share (¥)	12.2	(29.6)	8.5	(8.2)	30.5
Dividends per share (¥)	6.0	4.0	4.0	4.0	6.0
Total assets (¥ billion)	762.1	762.4	768.4	823.7	850.0
Interest-bearing debt (¥ billion)	261.0	270.8	281.5	308.2	310.0
EBITDA (¥ billion)*3	86.3	59.2	63.7	82.1	93.0

*1 ROA= Operating income/Total assets

*2 ROE= Net income/Shareholders' equity

*3 EBITDA = Operating income + Depreciation & amortization

Disclaimer Regarding Forward-Looking Statements and Business Risks

Disclaimer

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Business Risks

The Teijin Group recognizes certain risks as having the potential to affect its operating results and/or financial position. As of the date of this document, these risks included, but were not limited to, the risks listed below.

(1) Market-related risk

The Teijin Group manufactures and sells products, the sales of which may be affected by market conditions, competition with other companies and price fluctuations arising thereof, as well as fluctuations in raw materials prices and fuel costs, and such market factors as fluctuations in foreign exchange and interest rates.

(2) Product quality risk

The Teijin Group has established a dedicated division that is charged with product quality and reliability assurance for all Group businesses. However, product and service defects arising from quality issues have the potential to negatively affect, among others, the Group's operating results, financial position and public reputation.

(3) R&D-related risk

The Teijin Group actively allocates management resources to R&D efforts. R&D in the pharmaceuticals business, in particular, is characterized by significant investments of funds and time. Pharmaceuticals discovery research has a high incidence of failure to discover promising drugs. There are also risks that plans to apply for regulatory approval may be abandoned or that approval may be rescinded.

(4) Risks related to overseas operations

The Teijin Group has operations overseas. These operations are vulnerable to the impact of fluctuations in foreign exchange rates, as well as enforcement of new or unexpected changes to existing laws, regulations or tax systems that exert an adverse impact on the Group; economic fluctuations; or social unrest triggered by acts of terror or war.

(5) Risks related to accidents and disasters

In the event of a major natural disaster or unforeseen accident that results in damage to the Teijin Group's production facilities or significantly impedes the Group's supply chain, such developments may have a negative impact on the Group's operating results and/or financial position.

◆ Consolidated balance sheets

(¥ billion)	Sept. 30, 2013	Dec. 31, 2013	Mar. 31, 2014	June 30, 2014	Sept. 30, 2014	Dec. 31, 2014	Mar. 31, 2015	June. 30, 2015
Total assets	766.8	791.0	768.4	783.8	779.8	832.7	823.7	816.4
Current assets	366.2	385.6	364.9	367.6	370.8	413.1	406.0	395.6
Fixed assets	400.6	405.4	403.5	416.2	409.0	419.6	417.7	420.8
Total liabilities and net assets	766.8	791.0	768.4	783.8	779.8	832.7	823.7	816.4
Liabilities	471.3	489.3	468.3	483.8	499.3	539.1	520.1	496.3
[Interest-bearing debt]	292.3	296.9	281.5	303.4	302.0	317.3	308.2	294.3
Net assets	295.5	301.7	300.1	300.0	280.5	293.6	303.6	320.2

Note: For more information, see Teijin's quarterly results report (Consolidated Financial Results for the First Quarter of FY15).


◆ Consolidated Statements of Income

	FY14				FY15	FY14 1Q vs FY15 1Q
	1Q	2Q	3Q	4Q	1Q	
(¥ billion)						
Net Sales	181.9	195.5	201.1	207.7	192.6	+10.7
Cost of sales	133.9	145.2	145.1	145.3	130.8	-3.1
Gross profit	48.0	50.3	56.0	62.4	61.7	+13.8
SG & A	43.1	43.0	43.5	47.9	45.3	+2.2
Operating income	4.8	7.3	12.4	14.5	16.4	+11.6
Nonoperating items, net	(0.2)	2.1	2.5	(1.1)	1.6	+1.7
(Balance of financial expenses)	0.1	(0.5)	(0.2)	(0.6)	0.5	+0.3
(Equity in earnings and losses of affiliates)	0.4	1.2	0.9	(0.1)	0.9	+0.5
Ordinary income	4.7	9.4	14.9	13.4	18.0	+13.3
Extraordinary items (net)	(0.8)	(41.2)	(4.1)	(3.2)	(1.3)	-0.5
Income before income taxes	3.9	(31.9)	10.8	10.2	16.7	+12.8
Income taxes	2.4	(5.7)	2.9	3.5	5.5	+3.1
Profit (loss) attributable to non-controlling interests	(0.1)	(2.2)	(0.0)	0.4	0.0	+0.2
Profit attributable to owners of parent	1.6	(24.0)	7.9	6.3	11.2	+9.5

Note: For more information, see Teijin's quarterly results report (Consolidated Financial Results for the First Quarter of FY15).


◆ Yen/Dollar, Yen/Euro exchange rates

◆ Dollar/Euro exchange rates




◆ CAPEX, depreciation & amortization, and R&D expenses

CAPEX/Depreciation & Amortization



R&D Expenses



◆ Sales of Principal Pharmaceuticals

(¥ billion)

Product	Target disease	FY14					FY15
		1Q	2Q	3Q	4Q	Annual Total	1Q
<i>Bonalon</i> ^{®*}	Osteoporosis	3.1	3.3	3.6	3.0	12.9	3.3
<i>Onealfa</i> [®]	Osteoporosis	1.4	1.4	1.5	1.2	5.4	1.3
Osteoporosis total		4.5	4.6	5.0	4.1	18.2	4.6
<i>Feburic</i> [®]	Hyperuricemia and gout	2.8	3.9	4.7	4.1	15.5	4.8
<i>Venilon</i> [®]	Severe infection	2.5	2.4	2.8	2.1	9.8	2.5
<i>Mucosolvan</i> [®]	Expectorant	1.6	1.4	1.9	1.5	6.5	1.8
<i>Laxoberon</i> [®]	Laxative	0.8	0.7	0.8	0.6	2.9	0.7
<i>Tricor</i> [®]	Hyperlipidemia	0.4	0.4	0.5	0.4	1.7	0.4
<i>Alvesco</i> [®]	Asthma	0.3	0.3	0.4	0.3	1.2	0.3
<i>Bonalfa</i> [®]	Psoriasis	0.3	0.3	0.3	0.2	1.1	0.3
<i>Somatuline</i> ^{®*}	Acromegaly and pituitary gigantism	0.2	0.3	0.3	0.3	1.1	0.3

* *Bonalon*[®] is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, NJ, U.S.A.

* *Somatuline*[®] is the registered trademark of Ipsen Pharma, Paris, France.

◆ **Development status by therapeutic area**

(As of June 30, 2015)

	Phase of Clinical Trials				
	Phase I	Phase II	Phase III	Filed	Approved/New Launch
Bone and joint disease		ITM-058 KTP-001			
Respiratory disease		PTR-36			NA872ET [Mucosolvan®]
Cardio-vascular and metabolic disease	TMG-123 TMX-049*	ITM-014N [Somatuline®] (New indication for neuroendocrine tumor) TMX-67XR [Feburic®]	TMX-67TLS [Feburic®] (New indication for tumor lysis syndrome) TMX-67 [Feburic®] (PRC)		
Other			GGs-ON, -MPA, -CIDP [Venilon®] (New indication for optic neuritis) (New indication for microscopic polyangiitis) (New indication for chronic inflammatory demyelinating polyneuropathy)		

* Clinical trials for TMX-049, the treatment of hyperuricemia and gout commenced in April 2015.

◆ Status of licensed-in products in preclinical stages (information for the past three years)

Agreement	Licensor	Nature of Agreement
May 2014	Sigma-Tau Pharma Ltd. (U.K.)	Exclusive development and distribution rights in Japan for EZN-2279, a therapeutic agent for adenosine deaminase (ADA) deficiency

◆ Status of licensed-in products for which applications for approval to manufacture and market have been filed

Agreement	Licensor	Nature of Agreement
March 2015	Taisho Pharmaceutical Co., Ltd. (Japan)	Distribution rights in Japan for TT-063, an anti-inflammatory analgesic patch containing the compound S-flurbiprofen for which the anticipated indication is osteoarthritis

◆ Newly developed pharmaceutical candidates

【Approved】

(As of June 30, 2015)

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
NA872ET (ambroxol hydrochloride)	Expectorant	Small, sustained-release tablet-form version of <i>Mucosolvan</i> (ambroxol hydrochloride) that is smaller than <i>Mucosolvan</i> L Capsule and thus easier to take. This version is promising because it allows easier apportioning of single doses.	Tablet	Licensed in from Boehringer Ingelheim GmbH (Germany) Approved in Japan in February 2015.

【Phase III】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
GGs-ON (freeze-dried sulfonated human immunoglobulin)	Optic neuritis	The immunoregulatory mechanism of this drug inhibits inflammation of the optic nerve; also promising because of its ability to restore lost visual function.	Injection	Under joint development with Kaketsuken (New indication)
GGs-MPA (freeze-dried sulfonated human immunoglobulin)	Microscopic polyangiitis	This drug's anti-inflammatory and immunoregulatory actions mitigate autoimmune vasculitis; also promising as a treatment for mononeuritis multiplex, a neuropathic disorder that is not alleviated by standard therapies.	Injection	Under joint development with Kaketsuken (New indication)
GGs-CIDP (freeze-dried sulfonated human immunoglobulin)	Chronic inflammatory demyelinating polyneuropathy	The immunoregulatory action of this drug inhibits inflammation of the peripheral nerves; the drug thus offers promise as a treatment that will restore lost muscle strength.	Injection	Under joint development with Kaketsuken (New indication)
TMX-67TLS (febuxostat)	Tumor lysis syndrome	A highly potent drug that selectively inhibits xanthine oxidase. Offers promise as a once-daily treatment option that prevents hyperuricemia in patients with malignant tumors who have undergone chemotherapy.	Tablet	Developed in-house (New indication)
TMX-67 (febuxostat)	Hyperuricemia and gout	Trials to facilitate the licensing out of febuxostat (tablet-form treatment for hyperuricemia and gout currently sold in Japan and elsewhere) for sale in the PRC. A highly potent drug that selectively inhibits xanthine oxidase and is also safe for patients with impaired renal function who may be unable to tolerate existing treatments. Offers promise as a new treatment option that will improve the quality of life of hyperuricemia and gout sufferers in the PRC.	Tablet	Under joint development with Astellas Pharma China, Inc.

【Phase II】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
ITM-014N (lanreotide acetate)	Neuroendocrine tumors	Promising for the treatment of neuroendocrine tumors; inhibits cell proliferation and improves associated symptoms by interacting with somatostatin receptors to induce apoptosis (direct mechanism) and by blocking the release of neurotrophic factors (indirect mechanism).	Injection	Licensed in from Ipsen Pharma SAS (France) (New indication)
ITM-058	Osteoporosis	Promising for the treatment of osteoporosis due to potency in promoting bone formation, resulting in a rapid increase in bone density and reduction in the risk of fracture. Superior to existing PTH derived drugs in its ability to increase bone density and its safety (minimal risk of hypercalcemia).	Injection	Licensed in from Ipsen Pharma SAS (France)
KTP-001	Lumbar disc herniation	For use in chemonucleolysis for herniated lumbar discs; because it is a recombinant human protease—identical in structure to matrix metalloprotease, which promotes the spontaneous regression of herniated discs—this drug minimizes the risk of allergic reaction and facilitates the selective treatment of affected discs, thus reducing damage to surrounding tissue and enhancing the viability of this procedure as a minimally invasive alternative to surgery and expanding the treatment options available to patients.	Injection	Engineered by Professor Hirotaka Haro and Dr. Hiromichi Komori; under joint development with Kaketsuken

【Phase II】(continued)

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
TMX-67XR (febuxostat)	Hyperuricemia and gout	Sustained-release formulation of hyperuricemia and gout treatment febuxostat, which is currently on the market.	Oral	Developed in-house (new formulation)
PTR-36	Bronchial asthma	Uses a novel mechanism (CRTh2 receptor antagonism) to control symptoms of asthma, facilitating effective long-term management of the disease; offers promise for use alone, delivering therapeutic value comparable to that of steroids, for patients with mild asthma; also offers promise for use in tandem with steroid inhalants, delivering sufficient therapeutic value for patients with mild to severe asthma.	Tablet	Licensed in from Pulmagen Therapeutics (Asthma) Limited

【Phase I】

Code No. (Generic name)	Target disease	Medical properties/characteristics	Dosage form	Remarks
TMG-123	Type 2 diabetes	Uses a novel mechanism (activation of glucokinase (GK) expressed predominantly in the liver) to control blood glucose levels; holds promise for use by patients with impaired glucose homeostasis. Also expected to offer greater convenience (administered once daily, does not require adjustment of dose for patients with renal insufficiency and minimal risk of drug interaction).	Tablet	Developed in-house
TMX-049	Hyperuricemia and gout	Non-purine xanthine oxidase inhibitor; offers promise as a new treatment for hyperuricemia and gout that is both highly effective and safe.	Tablet	Developed in-house

TEIJIN

Human Chemistry, Human Solutions

Human Chemistry, Human Solutions

The promise of the Teijin brand is summed up in the resonant statement: "Human Chemistry, Human Solutions".

Our promise is to continue to develop chemical technologies that are friendly to both people and the global environment. It is to keep providing solutions that deliver the real value that society and our customers expect.

We will certainly keep this promise. Constantly working to enhance the Quality of Life –our very reason for being as a company– the Teijin Group will continue to win the trust of society and our customers.